OXIGENE INC (OXGN)
(Delayed Data from NSDQ)
$0.70 USD
-0.03 (-3.69%)
Updated Jun 17, 2016 03:59 PM ET
After-Market: $0.72 (%) 10:04 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Oncotelic Therapeutics, Inc. [OXGN]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Squarely FOCUSed on Initiating Phase 2/3 Trial by Mid-Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Update: Updated Clinical Strategy Pairs Vascular Disruptors with SOC
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CA4P Shows Early Signs of Activity in Neuroendocrine Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Management Sets Lofty Goal to Top the Standard of Care in Refractory Ovarian Cancer; Revising PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Update - Multifaceted Attack on Tumor Vasculature for Planned Pivotal Ovarian Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Guidance Delivered-FDA Gives Thumbs Up for Ovarian Trial Design
Provider: H.C. WAINWRIGHT & CO., INC.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Update-Key FDA Guidance Expected in June
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2015 AACR Meeting Highlights-Cancer Gets a Dose of Brotherly Love
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Update-Pivotal Trial in Ovarian Cancer Could Start by Year?s End
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cracking Platinum Resistance with the Right Combination of Drugs
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Update-ZYBRESTAT Hits PFS in Resistant Ovarian Cancer
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are reiterating our Buy rating and a 12-month target price of $6
Provider: H.C. WAINWRIGHT & CO., INC.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for OXGN
Provider: VALUENGINE, INC
|